IL13 is thought to play a central role in promoting mucus production associated with asthma and COPD, making IL13 neutralizing biologics the focus of both an approved therapeutic, dupilumab, and multiple other ongoing clinical trials (28–31). This evidence concerns the gene IL13 and chronic obstructive pulmonary disease.